Cardioprotective Effect of Quercetin and Sitagliptin in Doxorubicin-Induced Cardiac Toxicity in Rats.
cardiotoxicity
doxorubicin
quercetin
rats
sitagliptin
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
01
2021
accepted:
25
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
A previous study revealed a pronounced protective effect of combining quercetin (QC) with sitagliptin (STN) in testicular tissue. Accordingly, this study was designed to evaluate the cardioprotective effects of QC and STN each alone or in combination in doxorubicin (DOX)-induced cardiotoxicity in the rats. Thirty male adult Wistar rats were divided into five groups: the first group (control) treated with sodium chloride, the second group treated with DOX (3 mg/kg I.P. injection), the third group treated with DOX with a combination of QC (80 mg/kg), and STN (10 mg/kg), the fourth group treated with DOX and QC and the fifth group treated with DOX and STN. Blood was collected on day 22 and used for assessment of serum troponin, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), total lipid profile, C-reactive protein (CRP), and total antioxidant capacity (TAOC). Atherogenic indices were also calculated. Cardiac tissue was sent for histopathological analysis. DOX produced a significant increase in the level of troponin, LDH, CKP, CRP, total cholesterol (TC), low-density lipoprotein (LDL), triglycerides (TG), and atherogenic index of plasma; and significantly decreased TAOC. The combination of quercetin and sitagliptin was more effective than each treatment alone in restoring the level of troponin, LDH, CKP, CRP, Cholesterol, LDL, TG, atherogenic index of plasma and significantly increased TAOC compared to DOX treated group. The histopathological finding also supports the biochemical results. The study revealed the cardioprotective effects of the combination of QC and STN which could be attributed to the additive effects of this combination through antioxidant, anti-inflammatory, lipid lowering and anti-atherogenic activities; suggesting it as a good therapeutic candidate to be tested in the clinical setting.
Identifiants
pubmed: 33737832
doi: 10.2147/CMAR.S300495
pii: 300495
pmc: PMC7965691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2349-2357Informations de copyright
© 2021 Aziz.
Déclaration de conflit d'intérêts
The author reports no conflicts of interest in this work.
Références
Sci Rep. 2016 Jul 29;6:30812
pubmed: 27470932
Arch Razi Inst. 2020 Mar;75(1):55-62
pubmed: 32292003
Trends Pharmacol Sci. 2015 Jun;36(6):326-48
pubmed: 25895646
Indian J Pharmacol. 2011 Sep;43(5):507-11
pubmed: 22021990
J Cardiovasc Pharmacol. 2014 Nov;64(5):412-9
pubmed: 24949584
Diabetes Metab. 2017 Feb;43(1):48-58
pubmed: 27745828
BMC Cardiovasc Disord. 2019 Oct 29;19(1):239
pubmed: 31664919
Eur Heart J. 2019 Jun 7;40(22):1771-1777
pubmed: 29982507
Biochim Biophys Acta. 2002 Dec 23;1567(1-2):150-6
pubmed: 12488048
Fitoterapia. 2015 Oct;106:256-71
pubmed: 26393898
Diabetes Metab Syndr Obes. 2017 Jun 07;10:207-222
pubmed: 28652790
Bosn J Basic Med Sci. 2007 Aug;7(3):212-7
pubmed: 17848144
Clin Exp Pharmacol Physiol. 2018 Jul;45(7):628-635
pubmed: 29679391
J Med Food. 2010 Aug;13(4):905-10
pubmed: 20482278
J Nutr Metab. 2018 Jul 4;2018:7027624
pubmed: 30116641
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
J Cardiovasc Pharmacol. 1999 Nov;34(5):711-7
pubmed: 10547088
Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75
pubmed: 28185035
Phytother Res. 2015 Mar;29(3):444-9
pubmed: 25640007
Toxicol Appl Pharmacol. 2019 Feb 15;365:30-40
pubmed: 30576699
Front Pharmacol. 2020 Apr 07;11:422
pubmed: 32317975
Mediators Inflamm. 2016;2016:9340637
pubmed: 28003714
Eur Heart J. 2019 Jan 21;40(4):336-344
pubmed: 30601998
Acta Diabetol. 2016 Jun;53(3):461-8
pubmed: 26687195
Arq Bras Cardiol. 2020 Jul;115(1):102-108
pubmed: 32813833
Drug Des Devel Ther. 2019 Sep 20;13:3321-3329
pubmed: 31571833
Am J Clin Nutr. 2002 May;75(5):894-9
pubmed: 11976164
FEBS Lett. 2013 Jan 16;587(2):105-10
pubmed: 23219922
Endocr Pract. 2019 Jan;25(1):69-100
pubmed: 30742570
Ren Fail. 2015 May;37(4):687-93
pubmed: 25703705
Int J Mol Med. 2019 Sep;44(3):893-902
pubmed: 31524223
Adv Exp Med Biol. 2011;701:283-9
pubmed: 21445799
Am J Cardiol. 2012 Dec 15;110(12):1717-22
pubmed: 22981267
Biomed Res Int. 2013;2013:934239
pubmed: 24228260
Eur J Med Chem. 2018 Jul 15;155:889-904
pubmed: 29966915
SAGE Open Med. 2013 Sep 10;1:2050312113499912
pubmed: 26770677
Nutr Rev. 2020 Aug 1;78(8):615-626
pubmed: 31940027
Pharmacogenet Genomics. 2011 Jul;21(7):440-6
pubmed: 21048526